DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University.
| Company Name | DotBio Singapore |
|---|---|
| Brand Name | DotBio |
| Industries | Biotech |
| Year of Establishment | 2018 |
| Founder(s) | Ignacio Asial P?ÑR NORDLUND |
| No. of Employees | less than 10 |
| Regional Coverage | Singapore |
| Clients | / |
| Stage | Seed |
| Investor(s) | Enterprise Singapore Futec Biomedical Investments Limited |
| Fundraising History | 184K USD (Dec 2018) 2.3M USD (Jul 2018) |
| Raising Fund | / |
| Fundraising target | / |
| Pre-money valuation | / |
| Post-money Valuation | / |
| Media Exposure | BSA bureau market screener bioworld.com sipii.sdll.cn |
| Company Email | [email protected] |
[dcb id=160440]